Disruptions in sleep timing and feeding schedules can reduce microbial diversity and suppress SCFA production, both of which directly affect GLP-1 signaling capacity
For IDH1 inhibitor and carnitine synthesis inhibitor studies: cells pre-treated with the IDH1 inhibitor GSK864 (Ovcar8 cells: 10.565M, FT282 cells: 12.24M) or mildronate (145M for both cell lines), and various metabolites such as KG (330M), L-carnitine (1mM), O-Acetyl-Carnitine (1mM), Propionyl-L-carnitine (1mM), Butyryl-L-carnitine (1mM), Citrate (333nM), Succinate (1mM), nacetyl-l-cysteine (NAC, 0.5M) for a period of 5 days, replacing drugs and metabolites every other day
Your care team is there to walk you through it
High or frequent dosing is the main concern, and people with kidney, liver or other conditions are most at risk
Red or pink urine can mean blood is present, which is not normal and should be checked right away